» Articles » PMID: 22846040

Insights into the Inhibition of the P90 Ribosomal S6 Kinase (RSK) by the Flavonol Glycoside SL0101 from the 1.5 Å Crystal Structure of the N-terminal Domain of RSK2 with Bound Inhibitor

Overview
Journal Biochemistry
Specialty Biochemistry
Date 2012 Aug 1
PMID 22846040
Citations 25
Authors
Affiliations
Soon will be listed here.
Abstract

The p90 ribosomal S6 family of kinases (RSK) are potential drug targets, due to their involvement in cancer and other pathologies. There are currently only two known selective inhibitors of RSK, but the basis for selectivity is not known. One of these inhibitors is a naturally occurring kaempferol-α-L-diacetylrhamnoside, SL0101. Here, we report the crystal structure of the complex of the N-terminal kinase domain of the RSK2 isoform with SL0101 at 1.5 Å resolution. The refined atomic model reveals unprecedented structural reorganization of the protein moiety, as compared to the nucleotide-bound form. The entire N-lobe, the hinge region, and the αD-helix undergo dramatic conformational changes resulting in a rearrangement of the nucleotide binding site with concomitant formation of a highly hydrophobic pocket spatially suited to accommodate SL0101. These unexpected results will be invaluable in further optimization of the SL0101 scaffold as a promising lead for a novel class of kinase inhibitors.

Citing Articles

Designing a novel drug-drug conjugate as a prodrug for breast cancer therapy: in silico insights.

Muthumanickam S, Ramachandran B, Jeyakanthan J, Jegatheswaran S, Pandi B Mol Divers. 2024; 29(2):991-1007.

PMID: 38833125 DOI: 10.1007/s11030-024-10886-w.


Classifying protein kinase conformations with machine learning.

Reveguk I, Simonson T Protein Sci. 2024; 33(4):e4918.

PMID: 38501429 PMC: 10962494. DOI: 10.1002/pro.4918.


An Assessment of Dispersion-Corrected DFT Methods for Modeling Nonbonded Interactions in Protein Kinase Inhibitor Complexes.

Zhu Y, Alqahtani S, Hu X Molecules. 2024; 29(2).

PMID: 38257217 PMC: 11154270. DOI: 10.3390/molecules29020304.


Therapeutic targeting of p90 ribosomal S6 kinase.

Wright E, Lannigan D Front Cell Dev Biol. 2024; 11:1297292.

PMID: 38169775 PMC: 10758423. DOI: 10.3389/fcell.2023.1297292.


Comparison of Conformational Analyses of Naturally Occurring Flavonoid--Glycosides with Unnatural Flavonoid-CF-Glycosides Using Molecular Modeling.

Alkhodier R, Mishra S, Doerksen R, Colby D J Chem Inf Model. 2022; 63(1):375-386.

PMID: 36512328 PMC: 9904208. DOI: 10.1021/acs.jcim.2c01147.


References
1.
Chen S, Mackintosh C . Differential regulation of NHE1 phosphorylation and glucose uptake by inhibitors of the ERK pathway and p90RSK in 3T3-L1 adipocytes. Cell Signal. 2009; 21(12):1984-93. DOI: 10.1016/j.cellsig.2009.09.009. View

2.
Pearce L, Komander D, Alessi D . The nuts and bolts of AGC protein kinases. Nat Rev Mol Cell Biol. 2009; 11(1):9-22. DOI: 10.1038/nrm2822. View

3.
Bain J, Plater L, Elliott M, Shpiro N, Hastie C, McLauchlan H . The selectivity of protein kinase inhibitors: a further update. Biochem J. 2007; 408(3):297-315. PMC: 2267365. DOI: 10.1042/BJ20070797. View

4.
Taylor S, Kornev A . Protein kinases: evolution of dynamic regulatory proteins. Trends Biochem Sci. 2010; 36(2):65-77. PMC: 3084033. DOI: 10.1016/j.tibs.2010.09.006. View

5.
MONOD J, Wyman J, Changeux J . ON THE NATURE OF ALLOSTERIC TRANSITIONS: A PLAUSIBLE MODEL. J Mol Biol. 1965; 12:88-118. DOI: 10.1016/s0022-2836(65)80285-6. View